The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Open accessAbstract
Drug resistance presents a challenge to the treatment of cancer patients. Many studies have focused on cell-autonomous mechanisms of drug resistance. By contrast, we proposed that the tumour micro-environment confers innate resistance to therapy. Here we developed a co-culture system to systematically assay the ability of 23 stromal cell types to influence the innate resistance of 45 cancer cell lines to 35 anticancer drugs. We found that stroma-mediated resistance is common, particularly to targeted agents. We characterized further the stroma-mediated resistance of BRAF-mutant melanoma to RAF inhibitors because most patients with this type of cancer show some degree of innate resistance. Proteomic analysis showed that stromal cell secretion of hepatocyte growth factor (HGF) resulted in activation of the HGF receptor MET, reactivation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-OH kinase (PI(3)K)–AKT signalling pathways, and immediate resistance to RAF inhibition. Immunohistochemistry experiments confirmed stromal cell expression of HGF in patients with BRAF-mutant melanoma and showed a significant correlation between HGF expression by stromal cells and innate resistance to RAF inhibitor treatment. Dual inhibition of RAF and either HGF or MET resulted in reversal of drug resistance, suggesting RAF plus HGF or MET inhibitory combination therapy as a potential therapeutic strategy for BRAF-mutant melanoma. A similar resistance mechanism was uncovered in a subset of BRAF-mutant colorectal and glioblastoma cell lines. More generally, this study indicates that the systematic dissection of interactions between tumours and their micro-environment can uncover important mechanisms underlying drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, HGF has been implicated in mediating resistance to BRAF-targeted therapies by providing an alternative BRAF-independent mechanism for ERK–MAPK activation113.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [113]
In the citing paper
“By screening cancer-fibroblast co-cultures with a panel of cytotoxic and targeted agents, Straussman et al. identified that HGF-secreting fibroblasts rescued BRAF mutant melanoma cells from the BRAF inhibitor PLX4720 [99].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [99]
In the citing paper
“The tumor microenvironment is a complex ecosystem comprised of multiple cell types that support the growth of tumor cells, facilitate tumor progression, and modulate therapeutic response to anti-cancer treatments [29,99,100,120,121].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationKalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Self-citationSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Self-citationUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G. E., Hirth, P., Tsai, J. Y., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W. R., Zhang, C., Zhang, Y., Habets, G. G. M., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,875
Self-citationCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,001
Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance
Chen, F., Long, Q., Fu, D., Zhu, D., Ji, Y., Han, L., Zhang, B., Xu, Q., Liu, B., Li, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06860-4 · Cited by 124
Vacchelli, E., Galluzzi, L., Eggermont, A. M. M., Galon, J., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20459 · Cited by 122
Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression.
Koelwyn, G. J., Wennerberg, E., Demaria, S., & Jones, L. W. (2015) · PubMed · Cited by 130
Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin
Miao, L., Wang, Y., Lin, C. M., Xiong, Y., Chen, N., Zhang, L., Kim, W. Y., & Huang, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.027 · Cited by 119
Cancer Metastasis: A Reappraisal of Its Underlying Mechanisms and Their Relevance to Treatment
Riggi, N., Aguet, M., & Stamenkovic, I. (2017) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-044127 · Cited by 121
Kim, S. A., Lee, E. K., & Kuh, H. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.05.016 · Cited by 120
Stat3-Targeted Therapies Overcome the Acquired Resistance to Vemurafenib in Melanomas
Liu, F., Cao, J., Wu, J., Sullivan, K., Shen, J. L., Ryu, B., Xu, Z., Wei, W., & Cui, R. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.32 · Cited by 126
Roesch, A. (2014) · Oncogene · doi:10.1038/onc.2014.249 · Cited by 123
Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma
Zhou, L., YANG, K. Y., Andl, T., Wickett, R. R., & Zhang, Y. (2015) · Journal of Cancer · doi:10.7150/jca.10865 · Cited by 126
Sun, Y., Zhu, D., Chen, F., Qian, M., Wei, H., Chen, W., & Xu, J. (2016) · Oncogene · doi:10.1038/onc.2015.494 · Cited by 112
RetractedVilgelm, A. E., Pawlikowski, J. S., Liu, Y., Hawkins, O. E., Davis, T. A., Smith, J., Weller, K. P., Horton, L. W., McClain, C. M., Ayers, G. D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2405 · Cited by 115
Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights
Meador, C. B., & Hata, A. N. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107522 · Cited by 119
BRAF inhibitors in cancer therapy
Johansson, C. H., & Brage, S. E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.011 · Cited by 113
Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis
Chen, D., Liang, W., Yu, J., & Zhang, L. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2944 · Cited by 113
Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
Held, M. A., Langdon, C. G., Platt, J. T., Graham-Steed, T., Liu, Z. Z., Chakraborty, A. K., Bacchiocchi, A., Koo, A., Haskins, J. W., Bosenberg, M., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0408 · Cited by 114
BRAF inhibitors: resistance and the promise of combination treatments for melanoma
Griffin, M., Scotto, D., Josephs, D. H., Mele, S., Crescioli, S., Bax, H. J., Pellizzari, G., Wynne, M. D., Nakamura, M., Hoffmann, R. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19836 · Cited by 120
Lee, B. Y., Hogg, E. K. J., Below, C., Kononov, A., Blanco‐Gómez, A., Heider, F., Xu, J., Hutton, C., Zhang, X. M., Scheidt, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27607-8 · Cited by 115
HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
Papaccio, F., Della Corte, C. M., Viscardi, G., Di Liello, R., Esposito, G., Sparano, F., Ciardiello, F., & Morgillo, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113595 · Cited by 110
Zhou, B., Sun, C., Li, N., Shan, W., Lü, H., Guo, L., Guo, E., Xia, M., WENG, D., Li, M., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3442 · Cited by 108
Arandkar, S., Furth, N., Elisha, Y., Nataraj, N. B., van der Kuip, H., Yarden, Y., Aulitzky, W. E., Ulitsky, I., Geiger, B., & Oren, M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719076115 · Cited by 115
Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
Drakes, M. L., & Stiff, P. J. (2018) · Cancers · doi:10.3390/cancers10090302 · Cited by 115
Fabre, M., Ferrer, C., Domínguez-Hormaetxe, S., Bockorny, B., Murias, L., Seifert, O., Eisler, S. A., Kontermann, R. E., Pfizenmaier, K., Lee, S. Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2238 · Cited by 124
Determinants and functions of CAFs secretome during cancer progression and therapy
Linares, J., Marín-Jiménez, J. A., Badia-Ramentol, J., & Calon, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.621070 · Cited by 110
Gerosa, L., Chidley, C., Fröhlich, F., Sanchez, G., Lim, S. K., Muhlich, J. L., Chen, J.-Y., Vallabhaneni, S., Baker, G. J., Schapiro, D., et al. (2020) · Cell Systems · doi:10.1016/j.cels.2020.10.002 · Cited by 111
BRAF Gene and Melanoma: Back to the Future
Ottaviano, M., Giunta, E. F., Tortora, M., Curvietto, M., Attademo, L., Bosso, D., Cardalesi, C., Rosanova, M., Placido, P. D., Pietroluongo, E., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073474 · Cited by 125
BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes
Cooper, Z. A., Frederick, D. T., Juneja, V. R., Sullivan, R. J., Lawrence, D. P., Piris, A., Sharpe, A. H., Fisher, D. E., Flaherty, K. T., & Wargo, J. A. (2013) · OncoImmunology · doi:10.4161/onci.26615 · Cited by 109
Self-citationMechanisms of Drug Resistance in Melanoma
Winder, M. L., & Virós, A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_17 · Cited by 112
Irvine, M., Stewart, A., Pedersen, B., Boyd, S. C., Kefford, R. F., & Rizos, H. (2018) · Oncogenesis · doi:10.1038/s41389-018-0081-3 · Cited by 120
Tumor microenvironment in head and neck squamous cell carcinoma: Functions and regulatory mechanisms
Wang, G., Zhang, M., Cheng, M., Wang, X., Li, K., Chen, J., Chen, Z., Chen, S., Chen, J., Xiong, G., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.009 · Cited by 113
Targeting tumour microenvironment by tyrosine kinase inhibitor
Tan, H.-Y., Wang, N., Lam, W., Guo, W., Feng, Y., & Cheng, Y.-C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0800-6 · Cited by 107
Challenging resistance mechanisms to therapies for metastatic melanoma
Tentori, L., Lacal, P. M., & Graziani, G. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.10.003 · Cited by 114
Harbinski, F., Craig, V. J., Sanghavi, S., Jeffery, D. A., Liu, L., Sheppard, K. A., Wagner, S., Stamm, C., Buneß, A., Chatenay‐Rivauday, C., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0237 · Cited by 107
Fan, G., Yu, B., Tang, L., Zhu, R., Chen, J., Zhu, Y., Huang, H., Zhou, L., Liu, J., Wang, W., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj5705 · Cited by 116
The impact of tumor stroma on drug response in breast cancer
Dittmer, J., & Leyh, B. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.05.006 · Cited by 107
“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway
Cseh, B., Doma, E., & Baccarini, M. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.06.025 · Cited by 108
Shien, K., Papadimitrakopoulou, V. A., Ruder, D., Behrens, C., Shen, L., Kalhor, N., Song, J., Lee, J. J., Wang, J., Tang, X., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0148 · Cited by 109
Ferrari de Andrade, L., Ngiow, S. F., Stannard, K., Rusakiewicz, S., Kalimutho, M., Khanna, K. K., Tey, S.-K., Takeda, K., Zitvogel, L., Martinet, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1339 · Cited by 105
Phuchareon, J., McCormick, F. P., Eisele, D. W., & Tetsu, O. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510733112 · Cited by 107
Targeting Oncogenic Drivers and the Immune System in Melanoma
McArthur, G. A., & Ribas, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.5568 · Cited by 108
Self-citationBRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape
Smalley, I., Wargo, J. A., Flaherty, K. T., Messina, J. L., & Smalley, K. S. M. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.329 · Cited by 105
Self-citationMoreira, L., Bakir, B. S., Chatterji, P., Dantes, Z., Reichert, M., & Rustgi, A. K. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.12.004 · Cited by 112
Eiró, N., González, L. O., Fraile, M., Cid, S., Schneider, J., & Vizoso, F. J. (2019) · Cancers · doi:10.3390/cancers11050664 · Cited by 108
Overcoming tumor microenvironment obstacles: Current approaches for boosting nanodrug delivery
Wang, X., Zhang, H., Chen, X., Wu, C., Ding, K., Sun, G., Luo, Y., & Xiang, D. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.05.043 · Cited by 106
Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets
Palmieri, G., Ombra, M. N., Colombino, M., Casula, M., Sini, M. C., Manca, A., Paliogiannis, P., Ascierto, P. A., & Cossu, A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00183 · Cited by 110
Modulation of TNF-Induced Macrophage Polarization by Synovial Fibroblasts
Donlin, L. T., Jayatilleke, A., Γιαννοπούλου, Ε., Kalliolias, G. D., & Ivashkiv, L. B. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400486 · Cited by 108
Pietrantonio, F., Oddo, D., Gloghini, A., Valtorta, E., Berenato, R., Barault, L., Caporale, M., Busico, A., Morano, F., Gualeni, A. V., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0297 · Cited by 103
The Role of Hepatocyte Growth Factor (HGF) in Insulin Resistance and Diabetes
Oliveira, A. G., Araújo, T. G., Carvalho, B. D. M., Rocha, G. Z., Santos, A., & Saad, M. J. A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00503 · Cited by 106
Huang, J. C.-S., Basu, S. K., Zhao, X., Chien, S., Fang, M., Oehler, V. G., Appelbaum, F. R., & Becker, P. S. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.17 · Cited by 106
MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines
Vultur, A., Villanueva, J., Krepler, C., Rajan, G., Chen, Q., Xiao, M., Li, L., Gimotty, P. A., Wilson, M. A., Hayden, J., et al. (2013) · Oncogene · doi:10.1038/onc.2013.131 · Cited by 101
Mhawech-Fauceglia, P., Yan, L., Sharifian, M., Ren, X., Liu, S., Kim, G., Gayther, S. A., Pejovic, T., & Lawrenson, K. (2015) · Cancer Microenvironment · doi:10.1007/s12307-014-0153-7 · Cited by 95
Hepatic stellate cells: central modulators of hepatic carcinogenesis
Thompson, A., Conroy, K. P., & Henderson, N. C. (2015) · BMC Gastroenterology · doi:10.1186/s12876-015-0291-5 · Cited by 103
Tamburrino, A., Piro, G., Carbone, C., Tortora, G., & Melisi, D. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00056 · Cited by 102
Kesarwani, M., Kincaid, Z., Gomaa, A. R., Huber, E., Rohrabaugh, S., Siddiqui, Z., Bouso, M. F., Latif, T., Xu, M., Komurov, K., et al. (2017) · Nature Medicine · doi:10.1038/nm.4310 · Cited by 98
MYC and therapy resistance in cancer: risks and opportunities
Donati, G., & Amati, B. B. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13319 · Cited by 104
Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma
Kwong, L. N., & Davies, M. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0142 · Cited by 108
Epigenetic Regulation of the miR142-3p/Interleukin-6 Circuit in Glioblastoma
Chiou, G., Chien, C., Wang, M., Chen, M.-T., Yang, Y., Yu, Y., Chien, Y., Chang, Y., Shen, C., Chio, C., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.11.009 · Cited by 100
BRAF V600E mutation in hairy cell leukemia: from bench to bedside
Falini, B., Martelli, M. P., & Tiacci, E. (2016) · Blood · doi:10.1182/blood-2016-07-418434 · Cited by 102
Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies
Kim, M. H., & Kim, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2412-x · Cited by 102
HGF/c-MET Signaling in Melanocytes and Melanoma
Czyż, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123844 · Cited by 99
Impact of Tumor Microenvironment and Epithelial Phenotypes on Metabolism in Breast Cancer
Brauer, H. A., Makowski, L., Hoadley, K. A., Casbas-Hernandez, P., Lang, L. J., Romàn-Pèrez, E., D'Arcy, M., Freemerman, A. J., Perou, C. M., & Troester, M. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2123 · Cited by 96
Hippo pathway mediates resistance to cytotoxic drugs
Gujral, T. S., & Kirschner, M. W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703096114 · Cited by 91
Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer
Xu, S., Yang, Z., Jin, P., Yang, X., Li, X., Xiao, W., Wang, Y., Long, S., Zhang, T., Chen, G., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0927 · Cited by 100
Current State of Target Treatment in BRAF Mutated Melanoma
Tanda, E. T., Vanni, I., Boutros, A., Andreotti, V., Bruno, W., Ghiorzo, P., & Spagnolo, F. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00154 · Cited by 101
Weide, B., Eigentler, T., Pflugfelder, A., Zelba, H., Martens, A., Pawelec, G., Giovannoni, L., Ruffini, P. A., Elia, G., Neri, D., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0206 · Cited by 99
Qin, Q., Yu, R., Eriksson, J., Tsai, H., & Zhu, H. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216859 · Cited by 102
Chen, W.-L., Wang, D., Du, X., He, Y., Chen, S., Shao, Q., Ma, C., Huang, B., Chen, A., Zhao, P., et al. (2015) · Medical Oncology · doi:10.1007/s12032-015-0487-0 · Cited by 96
Young, H. L., Rowling, E. J., Bugatti, M., Giurisato, E., Luheshi, N., Arozarena, I., Acosta, J. C., Kamarashev, J. A., Frederick, D. T., Cooper, Z. A., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160855 · Cited by 95
Self-citationYaeger, R., Yao, Z., Hyman, D. M., Hechtman, J. F., Vakiani, E., Zhao, H., Su, W., Wang, L., Joelson, A., Cercek, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0768 · Cited by 94
Self-citationUniverses Collide: Combining Immunotherapy with Targeted Therapy for Cancer
Wargo, J. A., Cooper, Z. A., & Flaherty, K. T. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0477 · Cited by 94
Self-citationNiepel, M., Hafner, M. A., Pace, E. A., Chung, M., Chai, D. H., Zhou, L., Schoeberl, B., & Sorger, P. K. (2013) · Science Signaling · doi:10.1126/scisignal.2004379 · Cited by 93
Abumanhal-Masarweh, H., Koren, L., Zinger, A., Yaari, Z. A., Krinsky, N., Kaneti, G., Dahan, N., Lupu-Haber, Y., Suss-Toby, E., Weiss‐Messer, E., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.004 · Cited by 94
Rossi, A., Roberto, M., Panebianco, M., Botticelli, A., Mazzuca, F., & Marchetti, P. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172621 · Cited by 95
Drug resistance in colorectal cancer: An epigenetic overview
Luo, M., Yang, X., Chen, H.-N., Nice, E. C., & Huang, C. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188623 · Cited by 94
Wu, P., Han, J., Gong, Y., Liu, C., Yu, H., & Xie, N. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14101990 · Cited by 99
MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition
Amaral, T. M. S., Sinnberg, T. W., Meier, F. E., Krepler, C., Levesque, M. P., Niessner, H., & Garbe, C. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.012 · Cited by 95
Pan, X., Pei, J., Wang, A., Wen, S., Feng, L., Bu, F., Zhu, Y., Zhang, L., Wang, G., & Ouyang, L. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.022 · Cited by 95
Burbridge, M. F., Bossard, C. J., Saunier, C., Fejes, I., Bruno, A., Léonce, S., Ferry, G., Violante, G. D., Bouzom, F., Cattan, V., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0075 · Cited by 94
Liquid-based three-dimensional tumor models for cancer research and drug discovery
Ham, S. L., Joshi, R., Thakuri, P. S., & Tavana, H. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216643772 · Cited by 91
Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance
Pritchard, A. L., & Hayward, N. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0383 · Cited by 97
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
Merchant, M. A., Moffat, J. G., Schaefer, G., Chan, J., Wang, X., Orr, C., Cheng, J. H., Hunsaker, T., Shao, L., Wang, S. J., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185862 · Cited by 91
Sun, L., Huang, C., Zhu, M., Guo, S., Gao, Q., Wang, Q., Chen, B., Li, R., Zhao, Y., Wang, M., et al. (2020) · Theranostics · doi:10.7150/thno.49717 · Cited by 92
Corso, S., & Giordano, S. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0040 · Cited by 96
An unbiased metric of antiproliferative drug effect in vitro
Harris, L. A., Frick, P. L., Garbett, S. P., Hardeman, K. N., Paudel, B. B., Lopez, C. F., Quaranta, V., & Tyson, D. R. (2016) · Nature Methods · doi:10.1038/nmeth.3852 · Cited by 92
Sellmann, C., Doerner, A., Knuehl, C., Rasche, N., Sood, V. D., Krah, S., Rhiel, L., Messemer, A., Wesolowski, J. S., Schuette, M., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.753491 · Cited by 93
Pro-Survival Role of MITF in Melanoma
Hartman, M. L., & Czyż, M. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.319 · Cited by 96
Intratumoral bacteria may elicit chemoresistance by metabolizing anticancer agents
Geller, L. T., & Straussman, R. (2017) · Molecular & Cellular Oncology · doi:10.1080/23723556.2017.1405139 · Cited by 99
Self-citationWatson, S. S., Dane, M. A., Chin, K., Tatárová, Z., Liu, M., Liby, T. A., Thompson, W., Smith, R. L., Nederlof, M. A., Bucher, E., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.02.001 · Cited by 91
Resistance to antibody–drug conjugates: A review
Li, S., Zhao, X., Fu, K., Zhu, S., Pan, C., Yang, C., Wang, F., To, K. K. W., & Fu, L. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.12.036 · Cited by 100
Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy
Mandal, R., Becker, S., & Strebhardt, K. (2015) · Oncogene · doi:10.1038/onc.2015.329 · Cited by 93
Drug Resistance to EGFR Inhibitors in Lung Cancer
Tetsu, O., Hangauer, M. J., Phuchareon, J., Eisele, D. W., & McCormick, F. P. (2016) · Chemotherapy · doi:10.1159/000443368 · Cited by 88
Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma
Chan, X., Singh, A., Osman, N., & Piva, T. J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071527 · Cited by 96
Multiple murine BRafV600E melanoma cell lines with sensitivity to PLX4032
Jenkins, M. H., Steinberg, S. M., Alexander, M. P., Fisher, J. L., Ernstoff, M. S., Turk, M. J., Mullins, D. W., & Brinckerhoff, C. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12220 · Cited by 86
Diagnostic Immunohistochemistry in Cutaneous Neoplasia: An Update
Compton, L. A., Murphy, G. F., & Lian, C. G. (2015) · Dermatopathology · doi:10.1159/000377698 · Cited by 90
Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches
Hu, X., & Zhang, Z. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.11.003 · Cited by 94
The ERK cascade inhibitors: Towards overcoming resistance
Maik-Rachline, G., & Seger, R. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.12.001 · Cited by 91
Guo, J. X., Zeng, H., & Chen, Y. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00014 · Cited by 91
Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87
BRAF in Melanoma: Current Strategies and Future Directions
Salama, A. K. S., & Flaherty, K. T. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0779 · Cited by 86
Self-citationCell plasticity in cancer cell populations
Shen, S., & Clairambault, J. (2020) · F1000Research · doi:10.12688/f1000research.24803.1 · Cited by 91
Ilangumaran, S., Villalobos-Hernandez, A., Bobbala, D., & Ramanathan, S. (2016) · Cytokine · doi:10.1016/j.cyto.2015.12.013 · Cited by 82
Metadata
- Authors
- Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., Cooper, Z. A., Chapman, P. B., Solit, D. B., Ribas, A., Lo, R. S., Flaherty, K. T., Ogino, S., Wargo, J. A., & Golub, T. R.
- Affiliations
- Broad Institute (US)
- Dana-Farber Cancer Institute (US)
- Massachusetts General Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of California, Los Angeles (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Golub, Todd R.
- ORCID
- Venue
- Nature
- Published
- 2012-07
- Volume
- 487
- Issue
- 7408
- Pages
- 500-504
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3711467
- OpenAlex
- W2055624262
- Semantic Scholar
- d51bc0a1730710ad5e74705bff1a2f756c61fc28
- Cited by
- 1,771
- References
- 30
- Citations by year
- 2026: 51 · 2025: 48 · 2024: 68 · 2023: 93 · 2022: 98 · 2021: 102 · 2020: 114 · 2019: 115 · 2018: 138 · 2017: 150 · 2016: 154 · 2015: 172 · 2014: 215 · 2013: 196 · 2012: 53
- FWCI
- 82.21
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (R01CA166480, U54CA112962, P50CA093683, UM1CA186709)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- RAF inhibitors, vemurafenib, drug resistance, tumor microenvironment, stromal cells, hepatocyte growth factor, MAPK signaling, PI3K/Akt signaling, combination therapy, co-culture model, targeted therapy, non-specific immunity, cancer cell lines, proteomics, immunohistochemistry, immunofluorescence
- MeSH terms
- Vemurafenib, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Indoles, Melanoma, Mutation, Prognosis, Sulfonamides, Signal Transduction, Stromal Cells, Hepatocyte Growth Factor, Coculture Techniques, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Phosphatidylinositol 3-Kinases, Proteomics, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
